Lange et al. BMC Cancer (2018) 18:110
DOI 10.1186/s12885-017-3764-9

BMC Cancer

CORRECTION Open Access

Correction to: Impact of new generation hormone-therapy on cognitive function in elderly patients treated for a metastatic prostate cancer: Cog-Pro trial protocol

Marie Lange[1,2,3], Heidi Laviec[4], Hélène Castel[3,5], Natacha Heutte[1,2], Alexandra Leconte[2], Isabelle Léger[1,3,6,7], Bénédicte Giffard[3,8], Aurélie Capel[2], Martine Dubois[3,5], Bénédicte Clarisse[2], Elodie Coquan[2,4], Frédéric Di Fiore[9,10], Sophie Gouérant[9,10], Philippe Bartélémy[11], Laure Pierard[11], Karim Fizazi[12] and Florence Joly[1,2,3,13*]

Correction

After publication of the original article [1] the authors found that Table 2 had been formatted incorrectly, meaning that some rows in the Table did not display the correct information.

An updated version of Table 2 is included with this Correction.

The original article has also been updated.

Author details
[1]INSERM, U1086 ANTICIPE, Normandie University, UNICAEN, 14076 Caen, France. [2]Clinical Research Department, Centre François Baclesse, 14076 Caen, France. [3]Cancer and Cognition Platform, Ligue Nationale Contre le Cancer, 14076 Caen, France. [4]Medical Oncology Department, Centre François Baclesse, 14076 Caen, France. [5]Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, Normandie University, UNIROUEN, INSERM, DC2N, 76000 Rouen, France. [6]UPO, Gustave Roussy, 94800 Villejuif, France. [7]NeuroHIV Rehabilitation Unit, Bicêtre University Hospital, 94275 Le Kremlin Bicêtre, France. [8]Normandie University, UNICAEN, EPHE Paris, INSERM, U1077, 14000 Caen, France. [9]Medical Oncology Department, Centre Henri-Becquerel, 76000 Rouen, France. [10]Digestive and Urology Oncology Unit, Rouen University Hospital, 76000 Rouen, France. [11]Medical Oncology and Hematology Department, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France. [12]Medical Oncology Department, Gustave Roussy, 94800 Villejuif, France. [13]Medical Oncology Department, CHU de Caen, 14000 Caen, France.

Received: 9 November 2017 Accepted: 9 November 2017
Published online: 30 January 2018

Reference

1. Lange M, Laviec H, Castel H, Heutte N, Leconte A, Léger I, Giffard B, Capel A, Dubois M, Clarisse B, Coquan E, Di Fiore F, Gouérant S, Bartélémy P, Pierard L, Karim F, Joly F. Impact of new generation hormone-therapy on cognitive function in elderly patients treated for a metastatic prostate cancer: Cog-Pro trial protocol. BMC Cancer. 2017;17:549. https://doi.org/10.1186/s12885-017-3534-8.

* Correspondence: f.joly@baclesse.unicancer.fr
[1]INSERM, U1086 ANTICIPE, Normandie University, UNICAEN, 14076 Caen, France
[2]Clinical Research Department, Centre François Baclesse, 14076 Caen, France

Table 2 Used cognitive tests, questionnaires and biological tests

Evaluations	Before inclusion	At inclusion (baseline) [b]	3 months	6 months	12 months
Signed Informed Consent	✓				
Previous medical history	✓				
Cognitive assessment [a] MoCA Grober-Buschke test Digit span forward and backward (WAIS-III) Code (WAIS III) Trail Making test Doors test Stroop Victoria Verbal fluencies Rey-Osterrieth Complex Figure Number location (VOSP) Years of education and fNART		✓ ✓ Only at inclusion	✓	✓	✓
Quality of life FACT-G, FACIT-F, FACT-Cog, HADS, ISI		✓	✓	✓	✓
Pain (VAS)	✓ [c]	✓	✓	✓	✓
ONLY for PATIENTS (group of interest and control group)					
Geriatric assessment [d] G8 Charlson ADL IADL MNA Time up and go		✓	✓	✓	✓
Quality of life FACT-P		✓	✓	✓	✓
Adherence evaluation [e] Morisky questionnaire Patient diary			✓	✓	✓
Biological tests [f]		✓	✓	✓	✓
Specific blood samples for further research [g]		✓			

MoCA Montreal Cognitive Assessment, *WAIS* Wechsler Adult Intelligence Scale, *VOSP* Visual Object and Space Perception Battery, *fNART* French National Adult Reading Test, *ISI* Insomnia Severity Index, *VAS* Visual Analog Scale, *ADL* Activities of Daily Living, *IADL* Instrumental Activities of Daily Living, *MNA* Mini-Nutritional Assessment

[a]Cognitive assessment will be performed by neuropsychologists

[b]For group of interest patients: before the start of the treatment or within 15 days after the start of treatment by abiraterone acetate or enzalutamide

[c]Had to be ≤3 on the 0–10 pain VAS scale to meet with inclusion pain criteria

[d]Geriatric assessment will be performed by a study nurse specialized in geriatric

[e]Adherence evaluation will be performed only in group of interest patients

[f]At each time: CBC, platelets, albumin, CRP, prealbumin, iron, ferritin, transferrin, creatinin, sodium, potassium, ALT, AST, GGT, ALP, total bilirubin, TSH, T4, testosterone. At inclusion only: cortisol (at 8 h AM, fasting)

[g]1 EDTA (5 ml), 1 dry tube with gel (5 ml) and 1 dry tube without gel (5 ml)